Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

4.5%

1 terminated/withdrawn out of 22 trials

Success Rate

88.9%

+2.4% vs industry average

Late-Stage Pipeline

68%

15 trials in Phase 3/4

Results Transparency

0%

0 of 8 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
13(65.0%)
Phase 2
2(10.0%)
Phase 3
2(10.0%)
N/A
1(5.0%)
Phase 1
1(5.0%)
Early Phase 1
1(5.0%)
20Total
Phase 4(13)
Phase 2(2)
Phase 3(2)
N/A(1)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials
NCT03754634Phase 2Completed

A Prospective, Open, Multicenter Clinical Trial of Eltrombopag Combined With Diacerein in Eltrombopag-inefficient or Relapsed ITP

Role: collaborator

NCT03563690Not ApplicableCompleted

Different Kinds of Acupuncture Treatment for Knee Osteoarthritis

Role: collaborator

NCT02745717Phase 4Completed

The Efficacy of Immunosuppressive Therapy Combined With Cord Blood Transfusion in Treatment of Severe Aplastic Anemia

Role: collaborator

NCT04988425Phase 1Unknown

TNFα Monoclonal Antibody for Acute Spinal Cord Injury

Role: collaborator

NCT04481841Early Phase 1Unknown

Head Yuanshi Dian Therapy in Burning Mouth Syndrome

Role: collaborator

NCT04938700Phase 4Unknown

Study on the Correlation Between Intestinal Microecology and Allergic Diseases in Children

Role: collaborator

NCT04150835Phase 4Unknown

Xingnaojing for Mild-to-severe Acute Ischemic Stroke

Role: collaborator

NCT04034641Phase 4Unknown

Effect of Probiotics on Helicobacter Pylori Eradication

Role: collaborator

NCT04132622Phase 4Unknown

Low Dose Euthyrox in Treatments of Paraquat Intoxication.

Role: collaborator

NCT02728180Phase 4Unknown

Xingnaojing for Moderate-to-severe Acute Ischemic Stroke (XMAS)

Role: collaborator

NCT03942185Phase 2Unknown

Chinese Herbal Medicine for Psoriasis Vulgaris: a Real World Study

Role: collaborator

NCT03903055Unknown

Study on High-risk MDS Patients Based on RNA-seq Technology

Role: lead

NCT03123770Phase 4Unknown

Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients

Role: collaborator

NCT02908958Phase 4Unknown

Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency

Role: collaborator

NCT01356511Phase 4Completed

High-dose Dexamethasone Versus Conventional Dose Prednisone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)

Role: collaborator

NCT01734057Phase 3Withdrawn

Recombinant Human Thrombopoietin (rhTPO) Combining Rituximab Versus High-dose Dexamethasone for Initial Treatment of Primary Immune Thrombocytopenia (ITP)

Role: collaborator

NCT01734044Phase 3Completed

rhTPO Combining Dexamethasone Versus High-dose Dexamethasone for Initial Treatment of ITP

Role: collaborator

NCT02094638Completed

Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study

Role: collaborator

NCT02134405Phase 4Unknown

Rebamipide in Combination With Esomeprazole in the Management of Asian Patients With Functional Dyspepsia

Role: collaborator

NCT02443064Phase 4Unknown

Pharmacokinetics/ Pharmacodynamics (PK/PD) Study of Vancomycin

Role: collaborator